193 related articles for article (PubMed ID: 35738030)
1. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
Santangelo O; Baldwin JM; Stogner J
Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
[TBL] [Abstract][Full Text] [Related]
2. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
[TBL] [Abstract][Full Text] [Related]
3. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
[TBL] [Abstract][Full Text] [Related]
4. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
Smith KE; Staton M
Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
[No Abstract] [Full Text] [Related]
5. 'Spice' Use Motivations, Experiences, and Repercussions among Veterans of the United States Armed Forces.
Stogner J; Baldwin JM; Wiercioch A
Subst Use Misuse; 2024; 59(8):1182-1189. PubMed ID: 38548662
[TBL] [Abstract][Full Text] [Related]
6. Brief report: Synthetic cannabinoid use among military personnel.
Stogner J; Santangelo O; Baldwin JM
Am J Addict; 2024 Jan; 33(1):96-99. PubMed ID: 37717217
[TBL] [Abstract][Full Text] [Related]
7. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
Timmerman A; Balcaen M; Coopman V; Degreef M; Pottie E; Stove CP
Harm Reduct J; 2024 Jul; 21(1):127. PubMed ID: 38951904
[TBL] [Abstract][Full Text] [Related]
8. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
[TBL] [Abstract][Full Text] [Related]
9. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
Zaurova M; Hoffman RS; Vlahov D; Manini AF
J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136
[TBL] [Abstract][Full Text] [Related]
10. [Intoxications with synthetic cannabinoids].
Zanen JG; Leegwater E; Schippers EF; Wilms EB
Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36943159
[TBL] [Abstract][Full Text] [Related]
11. [Intoxications with synthetic cannabinoids].
Zanen JG; Leegwater E; Schippers EF; Wilms EB
Ned Tijdschr Geneeskd; 2023 Feb; 166():. PubMed ID: 36752668
[TBL] [Abstract][Full Text] [Related]
12. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
[TBL] [Abstract][Full Text] [Related]
13. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
van Amsterdam J; Brunt T; van den Brink W
J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
[No Abstract] [Full Text] [Related]
15. Cannabis and Cannabinoids for Pain and Posttraumatic Stress Disorder in Military Personnel and Veterans.
Wolfgang AS; Hoge CW
JAMA Psychiatry; 2023 Sep; 80(9):869-870. PubMed ID: 37436761
[TBL] [Abstract][Full Text] [Related]
16. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
[TBL] [Abstract][Full Text] [Related]
17. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
Alam RM; Keating JJ
Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
[TBL] [Abstract][Full Text] [Related]
18. 'Synthetic cannabis': A dangerous misnomer.
Darke S; Banister S; Farrell M; Duflou J; Lappin J
Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944
[TBL] [Abstract][Full Text] [Related]
19. Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings.
Goncalves R; Labadie M; Chouraqui S; Peyré A; Castaing N; Daveluy A; Molimard M
Clin Toxicol (Phila); 2022 Apr; 60(4):458-463. PubMed ID: 34850659
[TBL] [Abstract][Full Text] [Related]
20. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
Banister SD; Connor M
Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
